StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP)

Stock analysts at StockNews.com initiated coverage on shares of MEI Pharma (NASDAQ:MEIP) in a note issued to investors on Monday. The firm set a “buy” rating on the stock.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus reissued a “hold” rating and set a $7.00 target price on shares of MEI Pharma in a research report on Friday, April 12th. TheStreet downgraded shares of MEI Pharma from a “c-” rating to a “d+” rating in a research report on Thursday, February 1st.

MEI Pharma Stock Performance

NASDAQ MEIP opened at $3.05 on Monday. The company has a market capitalization of $20.32 million, a price-to-earnings ratio of 1.03 and a beta of 0.77. The company’s 50-day simple moving average is $3.81 and its two-hundred day simple moving average is $5.23. MEI Pharma has a one year low of $3.03 and a one year high of $7.97.

MEI Pharma (NASDAQ:MEIP) last posted its earnings results on Tuesday, February 13th. The company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($1.46) by ($0.20). MEI Pharma had a net margin of 39.06% and a return on equity of 39.72%. Equities analysts expect that MEI Pharma will post 3.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in MEI Pharma stock. National Bank of Canada FI acquired a new position in MEI Pharma, Inc. (NASDAQ:MEIP) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned about 0.09% of MEI Pharma as of its most recent SEC filing. 52.38% of the stock is currently owned by hedge funds and other institutional investors.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.